Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF THE MTOR KINASE INHIBITOR CC-223 IN COMBINATION WITH ERLOTINIB OR ORAL AZACITIDINE IN ADVANCED NON-SMALL CELL LUNG CANCER

NCT01545947 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01545947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01545947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF THE MTOR KINASE INHIBITOR CC-223 IN COMBINATION WITH ERLOTINIB OR ORAL AZACITIDINE IN ADVANCED NON-SMALL CELL LUNG CANCER
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
May 1, 2012
Completion date
December 11, 2014
Enrollment
76 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, non-small cell lung cancer